A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies
This early-stage study is testing a new experimental cancer medication called CID-078 in humans for the very first time. Researchers want to see how safe the medication is and how well it works against advanced solid tumors that have not responded to standard treatments.
Adults aged 18 and older with advanced cancerous solid tumors that can be measured on imaging scans may be eligible. Participants must also meet specific health guidelines and have finished certain previous cancer treatments well before joining.
Participants will receive the experimental cancer medication CID-078 as a single treatment. Throughout the process, the medical team will closely monitor your health, safety, and how your body responds to the new drug.
This study is taking place at multiple locations in the United States, including cities in Florida, Massachusetts, and Michigan. The study is currently active, but it is not looking for new participants at this time.
- 1Testing a brand-new experimental cancer medication called CID-078
- 2Focuses on adults with advanced solid tumors that are difficult to treat
- 3The study is active, though it is not currently recruiting new patients
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.